The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

Conditions

  • Pre-Exposure Prophylaxis of HIV Infection

Intervention

  • Oral Lenacapavir (LEN)
  • F/TDF
  • Sub-cutaneous (SC) Lenacapavir (LEN)
  • Placebo SC LEN
  • PTM F/TDF
  • PTM Oral LEN
  • F/TAF (for US participants only)

Principal Investigator

  • Veltman, Jennifer

Sponsor

  • Gilead

*The source of data for this particular study is "ClinicalTrials.gov" and was last updated on 05/16/2024. Loma Linda University does not make any warranties, expressed or implied, with respect to such data, and, furthermore, assumes no liability for any party's use, or the results of such use of the data.

Request Information

Complete the form below to contact the study team and receive more information about this trial.